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& GLP-1 analogs) in addition to core therapy increased signiﬁ-
cantly from 4.6% to 10.2% (p-value < 0.001), primarily due to
increased use of Byetta®. CONCLUSIONS: Removal of phar-
macy beneﬁt barriers improves an individual’s ability to achieve
optimal adherence to diabetes medication and thereby achieve
clinical goals. In conditions such as diabetes where optimal
therapy adherence has signiﬁcant implications, one should con-
sider decreasing or removing member cost share and other
beneﬁt barriers.
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OBJECTIVES: Racial disparities in diabetics exist in diabetes
control, as well as complications associated with diabetes. Such
disparities could lead to difference in likelihood of emergency
room (ER) visit among different races. This study examined the
association between patients’ race and ER in type 2 diabetes
patients newly starting oral antidiabetic therapy. METHODS:
This was a retrospective cohort study of Medicaid patients with
type-2 diabetes newly starting oral antidiabetic medication (met-
formin, sulfonylureas, thiazolidinediones). A cohort of type 2
diabetes patients was identiﬁed using ICD-9 code (250.xx) and
1 NDC code for antidiabetic medication. Information for demo-
graphic factors (race, age of patient, gender of the patient), clin-
ical factors (severity of diabetes, number of comorbidities),
medication related factors (number of medications consumed),
and access to care (number of diabetes related physician visits)
was extracted from the database. Patients’ race was categorized
as African Americans, Whites and Others. An ER visit was mea-
sured as a categorical dichotomous variable. Patients were fol-
lowed up for one year after the start date of new medication.
Multiple logistic regressions for three cohorts was performed to
assess the association patients’ race and likelihood of ER visit
adjusting for above mentioned factors. RESULTS: Among met-
formin users (n = 215), there was no difference in the likelihood
of ER visit between races. Among sulfonylureas users (n = 1171),
African Americans were associated with 51% increased likeli-
hood of ER visit as compared to whites (OR: 1.51, 95% CI:
1.14–2.0). Among thiazolidinedione users (n = 1751), there was
no difference in the likelihood of ER visit between races. Number
of medications and comorbidities were signiﬁcant predictors in
each of the analyses. CONCLUSION: Racial differences among
sulfonylureas users should be further investigated to understand
if there are disparities in other factors such as patients’ adher-
ence to sulfonylureas’ contributing to differences in ER use
between races.
DB3
TREATMENT EFFECT ESTIMATION:A COMPARISON
BETWEEN RANDOMIZED CONTROLLED TRIALS AND
OBSERVATIONAL STUDY WITH THREE DIFFERENT CAUSAL
EFFECT METHODS-PROPENSITY SCORE, MARGINAL
STRUCTURE MODEL AND DOUBLY ROBUST METHODS
Sun P1, Buesching D2, Obenchain R2
1Lilly Research Laboratories, Indianapolis, IN, USA, 2Eli Lilly and
Company, Indianapolis, IN, USA
OBJECTIVES: To examine whether results from two small ran-
domized controlled trials (RCTs) converge with the results from
a large observational study with causal effect methods (OSCEMs)
in comparing the treatment effects of 2 insulin regimens, and to
compare different causal effect methods including propensity
score (PSM), marginal structure model (MSM) and doubly robust
methods (DRM). METHODS: We ﬁrst theoretically examined
the similarity and difference as well as pros and cons of RCT and
OSCEM approaches in TE estimation. Then, 2 RCTs (n = 105
and 97; crossover at 16th weeks) and 3 large OSCEMs (n = 4519,
in 4 post-baseline quarters, propensity score, marginal structural
model and doubly robust methods) were conducted to examine
whether the differences of treatment effect between 2 insulin reg-
imens estimated through RCTs converge with the differences of
the same treatment effect estimated through 3 OSCEMs. The
treatment effect was deﬁned as the reduction of hemoglobin A1c
(HbA1c) among patients with type 2 diabetes. The 2 insulin reg-
imens were once-daily basal analog insulin (QDBAI)—glargine
vs. twice-daily premixed analog insulin (BIDMAI)—lispro mix
75/25. RESULTS: Theoretically, RCTs have higher internal valid-
ity and lower external validity compared to OSCEMs. The dif-
ferences of HbA1c reductions between BIDMAI and QDBAI in
4 quarters estimated through 2 RCTs were similar to the differ-
ences estimated through 3 OSCEMs (RCTs: −0.39—p = 0.02, 
−0.38—p = 0.03 vs. OSCEMs: −0.48—p < 0.01, −0.72—p = 0.12,
−0.31—p = 0.11). CONCLUSION: Compared to OSCEMs,
RCTs may have higher internal validity, but lower external valid-
ity. With correct exercises, the results of OSCEMs and RCTs can
converge. OSCEMs are larger sample methods that may have
better external validity, but require a large sample size. Compared
to PSM, MSM and DRM are less efﬁcient, may require an even
larger sample size.
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OBJECTIVES: The American Diabetes Association recommends
hemoglobin A1c tests be repeated within 3 months following an
above target result or a change in therapy. Our objective is to
examine how the frequency of retesting in clinical practice com-
pares to this recommendation. METHODS: A database of clin-
ical laboratory results linked to health plan claims (MarketScan
Lab) was used to identify patients receiving oral antidiabetic
therapy. Patients’ ﬁrst A1c test result between July 1, 2003 and
June 1, 2005 was classiﬁed as at target (less than 7), above target
(7–9), or poorly controlled (>9). The sample was restricted to
patients who had 6 months of claims histories prior to and after
the index test. Prescription drug claims were examined to iden-
tify therapy changes, deﬁned as adding a new medication or dis-
continuing one previously prescribed. Occurrence of A1c tests
within 6 months was assessed. RESULTS: 4836 patients were
identiﬁed, including 2450 (51%) who were at target, 1567
(32%) above target, and 819 (17%) poorly controlled. A1c
retesting occurred in 39.8% of patients with poor control,
35.6% of those above target, and 34.7% of those at target (p =
0.03). Among patients whose therapy was changed, retesting
occurred in 44.4% of those with poor control, 43.7% of those
above target, and 39.4% of those at target (p = 0.28). Rates of
retesting were higher among patients with commercial insurance
versus Medicaid, but the rate for poorly-controlled patients rel-
ative to those at target did not differ signiﬁcantly by insurance
status. CONCLUSION: There is little variation in the frequency
of retesting among diabetic patients at different A1c levels.
Retesting is more likely when patients change therapy; nonethe-
less a high proportion fails to be retested within 6 months. Clin-
ical practice has a long way to go to catch up with current A1c
testing guidelines, with implications for optimal treatment in
Type 2 diabetes.
